CAR T cell therapies to promote drug-free remission in lupus care
BMS’s CC-97540 and Cabaletta Bio’s CABA-201 highlight CAR T’s potential to achieve lasting drug-free remission, marking a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Bristol Myers Squibb
mRNA licensing agreements rise 800% in value as confidence grows beyond vaccines
With growing confidence in this technology, key companies are investing heavily in its potential to address unmet medical needs,…
S1P receptor modulators face uncertain future in Crohn’s disease amid trial setbacks
GlobalData’s Ulcerative Colitis Market Forecast expects Zeposia to have sales of $374.2 million worldwide in 2031, compared to…
Bristol Myers Squibb’s cell therapy gets USFDA nod for relapsed or refractory follicular lymphoma
95.7 per cent of patients responded to Breyanzi in the TRANSCEND FL trial
Bristol Myers Squibb opens new site in Hyderabad
The site will expand the company’s global drug development and IT & digital capabilities
BMS mezigdomide, iberdomide to transform multiple myeloma treatment landscape: GlobalData
The sales for mezigdomide and iberdomide are predicted to reach $125 million and $389 million, respectively
Pharma industry to hike prices on over 350 drugs in US
The increases are expected to come as the pharma industry prepares for the Biden Administration's Inflation Reduction Act (IRA),…
Claims against Dr Reddy’s over Revlimid in US dismissed
On 22nd December, 2022 and 27th December, 2022, the plaintiffs voluntarily dismissed Dr Reddy’s Laboratories Limited and Dr…
Anti-trust litigation filed against Dr Reddy’s Laboratories and other generic pharma companies in US
The complaint seeks damages for purported overpayments and equitable relief
US FDA approves Bristol Myers Squibb’s CAR-T cell therapy Breyanzi for relapsed large B-cell…
In the pivotal phase-III Transform trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of…